Thus, the focus of our study was to comprehensively analyse the metabolic benefits and drawbacks of GIPR agonist versus GIPR antagonist treatment in a lean mouse model, and a high‐fat‐diet (HFD)–induced obese mouse model with impaired glucose tolerance. This evidence concerns the gene GIPR and Impaired glucose tolerance.